A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative - PubMed (original) (raw)

Clinical Trial

A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative

J A DiPalma et al. Am J Gastroenterol. 2000 Feb.

Abstract

Objective: This study was designed to determine the efficacy and safety of a new laxative, Braintree polyethylene glycol (PEG) laxative (Miralax, Braintree Laboratories, Braintree, MA).

Methods: This investigation was designed as a placebo-controlled, blinded, randomized, multicenter parallel trial. Study subjects were constipated but otherwise healthy outpatients who had < or =2 stools during a 7-day qualification period. Braintree PEG laxative 17 g or dextrose placebo p.o. in 8 oz of water for a 14-day treatment period. A diary recorded each bowel movement and subjective symptoms of stool consistency, ease of passage, cramps, and flatus. CBC, blood chemistries and urinalysis were performed before and after the treatment period.

Results: There were 151 randomized subjects, 131 female and 20 male. An increase in bowel movement frequency was observed with the PEG laxative as compared to placebo (p<0.001), with the greatest difference in efficacy in wk 2 of treatment (p<0.001). By wk 2 of treatment, on average, placebo subjects had 2.7 bowel movements/wk and PEG-treated study subjects had 4.5 movements/wk (p<0.01), or more than one bowel movement every 2 days. Investigator (p<0.005) and patient (p<0.001) subjective assessment of perception of treatment effectiveness, and patient evaluations of stool consistency and passage showed significant improvement in the active treatment group (p<0.001). There were no significant differences in laboratory changes or adverse experiences recorded between groups.

Conclusion: Braintree PEG laxative is safe and effective in the short term for the treatment of constipation.

PubMed Disclaimer

Comment in

A new weapon for the arsenal in the war against constipation?
Lasch HM, Bozymski EM. Lasch HM, et al. Am J Gastroenterol. 2000 Feb;95(2):341-2. doi: 10.1111/j.1572-0241.2000.t01-1-01788.x. Am J Gastroenterol. 2000. PMID: 10685733 No abstract available.

Cited by

Cancer-related constipation.
Thomas J. Thomas J. Curr Oncol Rep. 2007 Jul;9(4):278-84. doi: 10.1007/s11912-007-0034-z. Curr Oncol Rep. 2007. PMID: 17588352 Review.
Constipation in adults.
Frizelle F, Barclay M. Frizelle F, et al. BMJ Clin Evid. 2007 Aug 1;2007:0413. BMJ Clin Evid. 2007. PMID: 19454117 Free PMC article.
Medical management of constipation.
Portalatin M, Winstead N. Portalatin M, et al. Clin Colon Rectal Surg. 2012 Mar;25(1):12-9. doi: 10.1055/s-0032-1301754. Clin Colon Rectal Surg. 2012. PMID: 23449608 Free PMC article.
Randomized, double-blind, placebo-controlled trial of polyethylene glycol (MiraLAX®) for urinary urge symptoms.
Bush NC, Shah A, Barber T, Yang M, Bernstein I, Snodgrass W. Bush NC, et al. J Pediatr Urol. 2013 Oct;9(5):597-604. doi: 10.1016/j.jpurol.2012.10.011. Epub 2012 Nov 3. J Pediatr Urol. 2013. PMID: 23127806 Free PMC article. Clinical Trial.
Prucalopride: the evidence for its use in the treatment of chronic constipation.
Coremans G. Coremans G. Core Evid. 2008 Jun;3(1):45-54. doi: 10.3355/ce.2008.011. Core Evid. 2008. PMID: 20694083 Free PMC article.

A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative - PubMed (original) (raw)